<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03711331</url>
  </required_header>
  <id_info>
    <org_study_id>2017_37</org_study_id>
    <secondary_id>2018-A00149-46</secondary_id>
    <nct_id>NCT03711331</nct_id>
  </id_info>
  <brief_title>Impact of a Strategy Based on Bacterial DNA Detection to Optimize Antibiotics in Patients With Hospital-acquired Pneumonia</brief_title>
  <acronym>VAPERO</acronym>
  <official_title>Impact of a Strategy Based on the Unyvero® Testing System on Appropriate and Targeted Antimicrobial Treatment in Patients With Suspected VAP or HAP Requiring Mechanical Ventilation: a Randomized Controlled Unblinded Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Curetis GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      VAPERO is a randomized, unblinded, controlled study to measure the impact of a strategy based
      on the Unyvero® multiplex PCR test on the adjustment of antimicrobial therapy in patients
      suspected with ventilator-associated or hospital-acquired pneumonia (VAP/HAP) requiring
      mechanical ventilation. The gold-standard microbiological diagnostic method for pneumonia in
      the ICU is still culture-based identification and antimicrobial susceptibility testing (AST)
      despite being more than a hundred years old, with results turnaround time spanning over
      several days, exposing patients to potentially inappropriate broad-spectrum antimicrobial
      therapy. The investigators aim to measure the impact of the Unyvero® testing strategy to
      improve the percentage of patients with VAP or HAP receiving early targeted antimicrobial
      therapy compared to standard care.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2020</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with targeted antibiotics regimen 24 hours after starting antimicrobial therapy in the experimental group compared to control group</measure>
    <time_frame>24 hours after the initiation of empiric antimicrobial therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients receiving appropriate antimicrobial therapy 24 hours after antibiotics initiation</measure>
    <time_frame>24 hours after antibiotics start Daily until 7 days after antibiotics start 14 days after antibiotics start 28 days after antibiotics start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of days alive and free from mechanical ventilation at day 28 after antibiotics initiation.</measure>
    <time_frame>24 hours after antibiotics start Daily until 7 days after antibiotics start 14 days after antibiotics start 28 days after antibiotics start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in Intensive Care Unit</measure>
    <time_frame>24 hours after antibiotics start Daily until 7 days after antibiotics start 14 days after antibiotics start 28 days after antibiotics start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patient Deaths</measure>
    <time_frame>at 28 days after antibiotics start</time_frame>
    <description>number of patient deaths after antibiotics start</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patient deaths in ICU</measure>
    <time_frame>24 hours after antibiotics start Daily until 7 days after antibiotics start 14 days after antibiotics start 28 days after antibiotics start</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Pneumonia, Ventilator-Associated</condition>
  <condition>Pneumonia, Bacterial</condition>
  <arm_group>
    <arm_group_label>FilmArray® Pneumonia panel plus strategy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients benefiting from the new strategy based on the system Unyvero ®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>patients benefiting from usual standard care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FilmArray® Pneumonia panel plus</intervention_name>
    <description>Early adjustment of antimicrobial therapy according to the results of the Unyvero® testing for patients suspected with VAP or HAP requiring MV.</description>
    <arm_group_label>FilmArray® Pneumonia panel plus strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard care</intervention_name>
    <description>Standard care, with broad-spectrum antimicrobial therapy unchanged until reception of traditional microbiology results</description>
    <arm_group_label>Standard care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients hospitalized in the ICU

          -  suspected with VAP or HAP requiring MV

        Exclusion Criteria:

          -  Severe immunodeficiency

          -  Moribund patients (SAPS II &gt; 90)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saad Nseir, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Saad Nseir, MD,PhD</last_name>
    <phone>320 44 44 95</phone>
    <phone_ext>+33</phone_ext>
    <email>saad.nseir@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>October 16, 2018</study_first_submitted>
  <study_first_submitted_qc>October 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2018</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ventilator-associated pneumonia</keyword>
  <keyword>Hospital-acquired pneumonia</keyword>
  <keyword>Antimicrobial therapy</keyword>
  <keyword>Ventilator-associated pneumonia Hospital-acquired pneumonia Antimicrobial therapy Polymerase chain reaction Antibiotics stewardship</keyword>
  <keyword>Polymerase chain reaction</keyword>
  <keyword>Antibiotics stewardship</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Healthcare-Associated Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Bacterial</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

